New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
November 20, 2014
18:00 EDTAGNPS Fund 1 sells 2.24M Allergan shares allocated to Valeant USA
Subscribe for More Information
08:02 EDTAMGNAmgen management to meet with UBS
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $323 from $291 at RBC Capital
Subscribe for More Information
07:11 EDTMRKBofA/Merrill to hold a conference
Subscribe for More Information
06:09 EDTSNYSanofi says has potential to launch up to six new drugs in 2015
Subscribe for More Information
05:22 EDTSNYRegeneron, Sanofi receive FDA Breakthrough Therapy designation in AD
Subscribe for More Information
November 19, 2014
09:28 EDTSHPGShire to establish Lexington, Massachusetts as U.S. operational headquarters
Subscribe for More Information
09:26 EDTSHPGShire appoints Poulton as interim CFO
Subscribe for More Information
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
08:17 EDTSNYRegeneron, Sanofi report new data from six alirocumab trials
Subscribe for More Information
07:52 EDTINFI, MRK, NVO, PFE, SNYInforma Business Information to hold a conference
Subscribe for More Information
07:11 EDTSNYSanofi drawing up list of CEO candidates to repalce Viehbacher, Reuters reports
Sanofi's (SNY) board is in the process of drawing up a short list of CEO candidates to replace Chris Viehbacher, sources tell Reuters. Jean-Rene Fourtou, a Sanofi director and the honorary chairman of media group Vivendi (VIVHY), has been selected to lead the appointments and governance committee that will select the next CEO. Smith & Nephew (SNN) CEO Olivier Bohuon, AstraZeneca (AZN) CEO Pascal Soriot and former Wyeth CEO Bernard Poussot have been rumored to be potential contenders for the CEO position. Reference Link
07:09 EDTAMGNJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
07:08 EDTSHPGSangamo says study demonstrates in vivo reversal of Huntington's disease signs
Subscribe for More Information
06:30 EDTJNJJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
05:51 EDTAGNStocks with implied volatility movement; AGN POT
Stocks with implied volatility movement; Allergan (AGN) 21, Potash (POT) 22 according to iVolatility.
November 18, 2014
17:15 EDTAGNPershing Square to discontinue proxy solicitation in connection with Allergan
Bill Ackman, CEO of Pershing Square, sent the following letter to the SEC. "Pershing Square Capital Management, L.P., a Delaware limited partnership, hereby respectfully requests the immediate withdrawal of the Definitive Proxy Statement on Schedule 14A, originally filed by Pershing Square with the United States Securities and Exchange Commission on September 24, 2014 (File No. 001-10269), along with any amendments and exhibits thereto. In light of the fact that Pershing Square has decided to discontinue its proxy solicitation in connection with the special meeting of Allergan, Inc. shareholders, it no longer believes it is desirable to pursue the matters referred to in the Proxy Statement. Definitive proxy materials with respect to the Special Meeting were filed by Pershing Square with the Commission on September 24, 2014 and November 14, 2014. If you have any questions or comments regarding the foregoing request for withdrawal, please feel free to contact Pershing Square’s counsel, Richard Brand of Kirkland & Ellis LLP at (212) 446-6454."
16:26 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
16:02 EDTAMGNAmgen presents long-term data on safety, efficacy of evolocumab
Subscribe for More Information
15:48 EDTSNYGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
13:34 EDTAGNActavis rallies after analysts push targets north of $300
Shares of drug maker Actavis (ACT) are climbing after a number of analysts cheered the company's acquisition of Allergan (AGN), and activist investor Bill Ackman said he supported the transaction, according to CNBC. WHAT'S NEW: Piper Jaffray analyst David Amsellem responded to Actavis' acquisition of Allergan by hiking his price target on the name to $338 from $280. The combined company has durable assets, a cost-efficient infrastructure, and the willingness to maintain a strong R&D infrastructure, contended Amsellem. Actavis' price-to-earnings ratio is likely to increase, since it has durable assets, while it his very likely to sustain growth of at least 10%, the analyst added. He kept an Overweight rating on the shares. Also extremely upbeat on Actavis following the deal was UBS analyst Marc Goodman. Actavis provides "the best value in the sector" following the deal, as the transaction should accelerate the company's revenue and profit growth, Goodman believes. That growth, in turn, should propel Actavis' price-to-earnings multiple higher, the analyst predicted. He hiked his price target on Actavis to $333 from $278 and kept a Buy rating on the stock. Meanwhile, Pershing Square's Bill Ackman said that he supported Actavis' takeover of Allergan, CNBC reported this morning. The owner of a large stake in Allergan, Ackman had been trying to get the drug maker to sell itself to Valeant (VRX). The activist investor said today that he would no longer push Allergan to hold a special meeting on December 18, CNBC noted. PRICE ACTION: In mid-afternoon trading, Actavis surged 7.5% to $266.50, while Allergan gained 2% to $214.
12:16 EDTSNYSanofi to host seminar on New Medicines
Subscribe for More Information
10:26 EDTAGNAckman to withdraw Allergan special meeting request, CNBC reports
Bill Ackman said he will withdraw his request for an Allergan (AGN) special meeting and that he supports the company's planned transaction with Actavis (ACT), according to CNBC's Scott Wapner. Reference Link
09:56 EDTAGNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Allergan (AGN) downgraded to Market Perform from Outperform at William Blair... Wells Fargo (WFC) downgraded to Market Perform from Outperform at BMO Capital... Allergan downgraded to Neutral from Buy at Guggenheim... Allergan downgraded to Neutral from Buy at SunTrust... Basic Energy (BAS) downgraded to Neutral from Buy at SunTrust... CBS (CBS) downgraded to Neutral from Overweight at Atlantic Equities... Key Energy (KEG) downgraded to Neutral from Buy at SunTrust... Macy's (M) downgraded to Neutral from Buy at BofA/Merrill... Statoil (STO) downgraded to Neutral from Overweight at JPMorgan... Urban Outfitters (URBN) downgraded to Market Perform from Outperform at Telsey Advisory... Urban Outfitters downgraded to Market Perform from Outperform at William Blair... Urban Outfitters downgraded to Neutral from Overweight at Atlantic Equities... Baker Hughes (BHI) downgraded to Hold from Buy at Argus.... Precision Drilling (PDS) downgraded to Market Perform at Raymond James.
09:23 EDTAMGNAmgen to host conference call
Management discusses Amgen's cardiovascular program, as well as the evolocumab data presented at the American Heart Association (AHA) Scientific Sessions 2014, on a conference call to be held on November 18 at 7 pm. Webcast Link
08:59 EDTAGNActavis deal positive, says Sterne Agee
Sterne Agee believes that the friendly nature of Actavis' (ACT) takeover of Allergan (AGN) will enable the combined companies to achieve greater revenue growth. The firm thinks the deal will enable the companies to integrate seamlessly, and it thinks that CEO Brent Saunders' experience at Forest and Bausch & Lomb will help him manage Allergan's leading ophthalmology franchises. Sterne keeps a Buy rating on Actavis.
08:33 EDTPFEPfizer announces availability of Trumenba vaccine
Pfizer announced hat TRUMENBA, the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States.
07:52 EDTAGNAllergan downgraded to Market Perform from Outperform at Wells Fargo
Subscribe for More Information
07:48 EDTAGNValeant not likely to raise bid for Allergan, says Canaccord
Subscribe for More Information
07:41 EDTAGNActavis provides best value in pharmaceutical sector, says UBS
UBS believes Actavis (ACT) provides the best value in the pharmaceutical sector following its deal to acquire Allergan (AGN). The firm pointed to the double digit accretion to earnings, synergies, and very attractive current valuation. UBS reiterated its Buy rating on Acatvis and raised its price target to $333 from $278.
07:29 EDTPFEPfizer less likely to pursue AstraZeneca after PD-L1 deal, says JPMorgan
Subscribe for More Information
07:18 EDTPFEWoodford confident in Astra, sees 50% chance of new Pfizer bid, Reuters reports
Investment manager Neil Woodford of Woodford Investment Management said he now has an even stronger belief in AstraZeneca (AZN), citing the company's strong product pipeline, and put the chances of a new takeover bid from Pfizer (PFE) at 50/50, reported Reuters, citing a statement from Woodford. Reference Link
07:03 EDTAMGNAmgen management to meet with UBS
Meeting to be held in Zurich on November 18 hosted by UBS.
06:49 EDTAGNValeant likely to pursue more moderate-sized deals, says Piper Jaffray
Subscribe for More Information
06:40 EDTAGNActavis price target raised to $338 from $280 at Piper Jaffray
Subscribe for More Information
06:39 EDTMRK, SHPG, PFEAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
06:18 EDTAGNAllergan downgraded to Neutral from Buy at Guggenheim
Subscribe for More Information
06:18 EDTAGNActavis price target raised to $310 from $290 at Leerink
Subscribe for More Information
06:15 EDTAGNActavis price target raised to $310 from $250 at Citigroup
Subscribe for More Information
06:11 EDTAGNAllergan downgraded to Neutral from Buy at SunTrust
SunTrust downgraded Allergan (AGN) to Market Perform citing the company's decision to be acquired by Actavis (ACT).
05:47 EDTAGNAllergan downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Allergan (AGN) to Market Perform citing the company's decision to be acquired by Actavis (ACT).
November 17, 2014
16:24 EDTAGNOn The Fly: Closing Wrap
Stocks on Wall Street were quiet and traded in a fairly narrow range for their sixth straight session, despite a "merger Monday" that saw over $100B in deals announced. The Dow and S&P, which began the week near record levels, passed back and forth across the flat line several times during the day, though the Nasdaq weakened early in the session and never really recovered. ECONOMIC EVENTS: In the U.S., industrial production fell 0.1% in October, missing expectations for it to have risen 0.2% from the prior month. October capacity utilization came in at 78.9%, which fell short of the expected 79.3% rate. The Empire State manufacturing index, which reflects manufacturing activity in the New York region, rose 4 points to 10.2 in November, which was generally in-line with the consensus forecast. In Asia, Japan's GDP unexpectedly shrank an annualized 1.6% last quarter, missing projections for a 2.2% gain and sinking its economy into a recession. COMPANY NEWS: Actavis (ACT) gained $4.17, or 1.71%, to $247.94 after confirming that it agreed to acquire Allergan (AGN) for a combination of $129.22 in cash and 0.3683 Actavis shares valued at approximately $66B, or $219 per Allergan share. Valeant Pharmaceuticals (VRX), which had been in a contentious fight to buy Allergan, commented that it "cannot justify to its own shareholders" paying a price of $219 or more per share for the Botox maker, whose stock rose $10.55, or 5.31%, to $209.20... Halliburton (HAL), conversely, fell $5.85, or 10.62%, to $49.23 after it agreed to acquire Baker Hughes (BHI) in a stock and cash transaction valued at $78.62 per Baker Hughes share, representing an enterprise value of $38B. When the deal talks were first reported by The Wall Street Journal last week, antitrust concerns were highlighted by analysts, but Halliburton said it had agreed to divest businesses that generate up to $7.5B in revenues, if required by regulators, and agreed to pay a fee of $3.5B if the transaction terminates due to a failure to obtain required approvals. Baker Hughes rose $5.34, or 8.92%, to $65.23 after the deal was announced. MAJOR MOVERS: Among the notable gainers was Celldex Therapeutics (CLDX), which advanced $4.09, or 28.88%, to $18.25 after the company reported it saw a statistically significant overall survival benefit, along with an increase in clinically meaningful tumor shrinkage, in a sub-group of its study of a drug to treat a specific type of brain tumor. Also higher was Amicus Therapeutics (FOLD), which rose $1.01, or 17.75%, to $6.70 after the company announced additional data on secondary endpoints from its second Phase 3 study of its treatment for Fabry disease. Among the noteworthy losers was William Lyon Homes (WLH), which fell $3.52, or 15.53%, to $19.14 after the company announced that it intends to offer, subject to market and other conditions, 1M tangible equity units, which will consist of a prepaid stock purchase contract and an amortizing note. Also lower were shares of DreamWorks (DWA), which dropped $3.71, or 14.26%, to $22.31 after multiple media outlets reported that talks about a takeover of the company by Hasbro (HAS) had ended. INDEXES: The Dow gained 13.01, or 0.07%, to 17,647.75, the Nasdaq lost 17.54, or 0.37%, to 4,671.00, and the S&P 500 added 1.50, or 0.07%, to 2,041.32.
15:40 EDTAGNActavis price target raised to $286 from $227 at BMO Capital
Subscribe for More Information
14:27 EDTPFEPfizer volatility flat into investor meeting
Subscribe for More Information
12:27 EDTAGNOn The Fly: Midday Wrap
Subscribe for More Information
12:12 EDTAGNActavis, Allergan deal 'great' for both companies, says BMO Capital
Subscribe for More Information
11:55 EDTMRKMerck says IMPROVE-IT study met all primary, secondary endpoints
Merck announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN – which combines simvastatin with the non-statin ZETIA -- experienced significantly fewer major cardiovascular events than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions. Merck plans to submit the data from IMPROVE-IT to the U.S. Food and Drug Administration in mid-2015 to support a new indication for reduction of major cardiovascular events for VYTORIN and ZETIA. VYTORIN and ZETIA are currently indicated for use along with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia. The current U.S. Prescribing Information for both products states that the effect of ezetimibe on cardiovascular morbidity and mortality, alone or incremental to statin therapy, has not been determined.
11:14 EDTAGNActavis says 2017 EPS goal of $25 does not include 'transformational' M&A
Subscribe for More Information
09:42 EDTPFEPfizer to host investor day
Subscribe for More Information
09:42 EDTAGNAllergan CEO says company insider trading suit against Ackman continuing
Subscribe for More Information
09:39 EDTAGNActavis CEO says 'aspirational goal' is to grow EPS to $25 by 2017
Subscribe for More Information
09:34 EDTAGNCombined Actavis-Allergan to be led by Actavis CEO Saunders
Actavis (ACT) and Allergan (AGN) said The combined company will be led by Brent Saunders, CEO and President of Actavis, and Paul Bisaro will remain Executive Chairman of the Board. The integration of the two companies will be led by the senior management teams of both companies, with integration planning to begin immediately in order to transition rapidly to a single company. Additionally, two members of the Allergan board of directors will be invited to join the Actavis Board of Directors following the completion of the transaction.
09:32 EDTAGNValeant says cannot justify paying $219 per share for Allergan
Valeant Pharmaceuticals (VRX) commented on the announcement that Allergan (AGN) and Actavis (ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock: "We have seen the announcement that Allergan and Actavis have made, and while we will review any such agreement in determining our course of action, Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan. Our business is performing extremely well as evidenced by our third quarter results, our expected strong fourth quarter, and our robust outlook for 2015, and I am confident in our continued ability to generate exceptional shareholder value. We will remain focused on delivering strong organic results and evaluating acquisition opportunities as we always have: prudently, in a disciplined manner, and in the best interests of our shareholders."
09:29 EDTAGNActavis to host conference call
Conference call to discuss the acquisition of Allergan will be held on November 17 at 10:30 am. Webcast Link
09:24 EDTAGNAllergan up over 5% to $209 after agreeing to be acquired by Actavis
Subscribe for More Information
09:22 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
09:21 EDTAGNActavis, Allergan transaction subject to approval of shareholders of both
Subscribe for More Information
09:20 EDTAGNActavis projects at least $1.8B in annual synergies from Allergan transaction
Subscribe for More Information
09:18 EDTAGNActavis sees free cash flow over $8B in 2016 following Allergan acquisition
Subscribe for More Information
09:16 EDTAGNActavis confirms deal to acquire Allergan for $219 in cash, stock
Subscribe for More Information
09:15 EDTAGNActavis confirms deal to acquire Allergan for $219 in cash and shares
Subscribe for More Information
09:10 EDTAGNActavis buying Allergan for $219 per share, CNBC reports
08:34 EDTMRKMerck says IMPROVE-IT met primary endpoint
Subscribe for More Information
08:13 EDTPFEPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
07:16 EDTSNY, PFE, JNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
06:43 EDTPFEAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
06:05 EDTAGNActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
05:27 EDTPFEPfizer lowers FY14 Reported EPS view to $1.40-$1.49 from $1.50-$1.59
Subscribe for More Information
05:23 EDTPFEPfizer forms strategic alliance with Merck KGaA
Subscribe for More Information
November 16, 2014
14:44 EDTSNYRegulus, Sanofi present new data enhancing the preclinical profile of RG-012
Subscribe for More Information
14:02 EDTAGNAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
13:26 EDTMRKMerck: KEYTRUDA showed superiority to chemotherapy for primary endpoint of PFS
Subscribe for More Information
12:56 EDTSNYGenzyme’s Lemtrada approved by the FDA
Genzyme, a Sanofi company, announced that the U.S. Food and Drug Administration has approved Lemtrada, alemtuzumab, for the treatment of patients with relapsing forms of multiple sclerosis. Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. “Today’s approval is the culmination of more than a decade of work by Genzyme to develop Lemtrada,” said Genzyme President and CEO, David Meeker. “Lemtrada demonstrated superior efficacy over Rebif on annualized relapse rates in the two studies which were the basis for approval. A comprehensive risk evaluation and mitigation strategy will be instituted in order to help detect and manage the serious risks identified with treatment.” The FDA approval of Lemtrada is based on two pivotal randomized Phase III open-label rater-blinded studies comparing treatment with Lemtrada to Rebif in patients with relapsing remitting MS who were either new to treatment or who had relapsed while on prior therapy . In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates; the difference observed in slowing disability progression did not reach statistical significance. In CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada vs. interferon beta-1a. The clinical development program for Lemtrada involved nearly 1,500 patients with more than 6,400 patient-years of safety follow-up. “The unmet need in MS remains high,” said Edward Fox, M.D., Ph.D., Director of the Multiple Sclerosis Clinic of Central Texas. “It is a great day for people living with relapsing forms of MS in the United States, who will now have access to this new meaningful treatment”.
November 14, 2014
17:27 EDTSHPGPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:13 EDTSHPGAppaloosa gives quarterly update on stakes
NEW STAKES: NXP Semiconductors (NXPI), Lorillard (LO), Alibaba (BABA), and Shire (SHPG). INCREASED STAKES: Whirlpool (WHR), Priceline (PCLN), Delta (DAL), CBS (CBS), and General Motors (GM). DECREASED STAKES: American Airlines (AAL), Disney (DIS), Apple (AAPL), MGM Resorts (MGM), and Eastman Chemical (EMN). LIQUIDATED STAKES: Expedia (EXPE), AIG (AIG), Prudential (PRU), Celanese (CE), and ASML Holding (ASML).
16:58 EDTSHPG, AMGNThird Point gives quarterly update on stakes
NEW STAKES: Alibaba (BABA), eBay (EBAY), Bed Bath & Beyond (BBBY), Shire (SHPG), and Parker Hannifin (PH). INCREASED STAKES: Actavis (ACT), Amgen (AMGN), EQT (EQT), Sensata (ST), Coca-Cola Enterprises (CCE). DECREASED STAKES: Williams Cos (WMB), Ally Financial (ALLY), Cheniere Energy (LNG), YPF (YPF), and FedEx (FDX). LIQUIDATED STAKES: AIG (AIG), T-Mobile (TMUS), Rackspace (RAX), Hertz (HTZ), and Citrix Systems (CTXS).
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJ, MRK, SNY, PFECVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
11:46 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
09:38 EDTAMGNJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).
09:37 EDTAMGNJANA reports new stakes in McDonald's, AECOM, Amgen
Subscribe for More Information
07:14 EDTAMGN, PFEAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
07:40 EDTSNYSanofi investor meeting timing tough in light of CEO ouster, Reuters says
Subscribe for More Information
07:38 EDTPFEBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,
07:23 EDTAGNValeant wooing doctors ahead of hoped for Allergan acquisition, WSJ says
Subscribe for More Information
November 12, 2014
16:53 EDTAGNAllergan receives FDA approval for new styles of NATRELLE 410
Subscribe for More Information
11:17 EDTMRK, SGEN, PFELeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:09 EDTAGNActavis in talks to buy Allergan for over $200 per share, Bloomberg says
Subscribe for More Information
10:01 EDTAGNActavis in talks to buy Allergan for $60B, more than $200/share Bloomberg says
Actavis (ACT) is said to seek to pay about $200 per share, but Allergan (AGN) seeks about $210 per share, according to Bloomberg.
08:13 EDTPFE, SNY, MRKBoston Biotech to hold a conference
Subscribe for More Information
08:02 EDTPFECredit Suisse to hold a conference
Subscribe for More Information
07:53 EDTSGENLeerink to hold a tour
Subscribe for More Information
07:01 EDTAGNAllergan announces approval of amendments to company bylaws
Subscribe for More Information
06:22 EDTAGNZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 11, 2014
16:05 EDTAMGNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
16:01 EDTMRKOptions Update; November 11, 2014
Subscribe for More Information
15:46 EDTAGNPershing Square, Sachem Head build 10% stake in Zoetis, WSJ reports
Subscribe for More Information
15:43 EDTPFE, SGEN, MRKLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:44 EDTAMGNAmgen reaffirms 2015 adjusted EPS outlook $9.05-$9.40
Subscribe for More Information
10:14 EDTSNYRegeneron data reinforce blockbuster potential of dupilumab, says Piper Jaffray
Piper Jaffray believes the Phase IIb results for dupilumab in patients with moderate to severe asthma reported by Regeneron (REGN) and partner Sanofi (SNY) reinforce the broad potential of the drug in a range of allergic diseases. The firm reiterates its $416 price target and Overweight rating on shares of Regeneron.
09:37 EDTMRKActive equity options trading
Subscribe for More Information
08:32 EDTAGNValeant likely to raise offer for Allergan again, says Bernstein
Subscribe for More Information
08:10 EDTMRKMerck reports results from Phase 2 study of Grazoprevir/Elbasvir
Subscribe for More Information
05:26 EDTSNYRegeneron, Sanofi announce dupilumab Phase 2b study met primary endpoint
Subscribe for More Information
November 10, 2014
15:54 EDTSNY, AMGNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
15:53 EDTSGENCredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link
09:20 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKGilead rises after Merck presents data on HCV combo
Subscribe for More Information
07:44 EDTJNJJohnson & Johnson looks for acquisitions to help expand in China, WSJ says
Subscribe for More Information
07:20 EDTMRKGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
07:05 EDTOREXOrexigen reports Q3 EPS 9c, consensus (13c)
Reports Q3 revenue $30.9M, consensus $8.93M; This increase in 2014 was due to recognition of two regulatory/development milestones, consisting of $20.0 million due upon regulatory approval in the U.S. and $10.0 million due upon the delivery of Contrave launch supplies to Takeda.
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naïve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
13:26 EDTAGNAckman's Allergan court win may prove costly down the road, Bloomberg says
When U.S. District Court Judge David Carter ruled on November 4 that Pershing Square can vote its 9.7% stake in Allergan (AGN) in a shareholder ballot aiming to remove Allergan directors, he also noted that there were “serious questions” regarding insider trading rules in the way Pershing Square acquired Allergan stock while preparing a bid with Valeant (VRX), says Bloomberg. Reference Link
November 7, 2014
16:07 EDTJNJJohnson & Johnson completes acquisition of Alios BioPharma
Subscribe for More Information
14:56 EDTAGNAllergan says Valeant offers to date inadequate, would consider increased bid
Subscribe for More Information
09:49 EDTAGNAckman says Allergan 'tipping scales' in Actavis’ favor, disadvantaging Valeant
Subscribe for More Information
06:48 EDTNVONovo Nordisk has a conference call hosted by JPMorgan
JPMorgan Analyst Gordon will host a conference call with CFO Jesper Brandgaard on November 14 at 10 am.
November 6, 2014
18:00 EDTINFIInfinity Pharmaceuticals sees FY14 loss $20M-$30M
Infinity Pharmaceuticals had seen FY14 loss at $170M-$180M.
16:26 EDTAMGNAmgen announces more than 50 abstracts accepted for presentation
Subscribe for More Information
16:09 EDTINFIInfinity Pharmaceuticals sees FY14 revenue $160M-$170M, consensus $127.78M
Subscribe for More Information
16:08 EDTINFIInfinity Pharmaceuticals reports Q3 EPS $2.03,may not compare to consensus (86c)
Subscribe for More Information
15:41 EDTJNJRulings encouraging for Boston Scientific in suit with J&J, says Wells Fargo
Subscribe for More Information
15:13 EDTMRK, SNYAmerican Association for Study of Liver Diseases to hold a meeting
Subscribe for More Information
10:30 EDTAGNAllergan disclosure today forced by SEC, CNBC's Faber reports
Subscribe for More Information
10:05 EDTAGNActavis talks to buy Salix put on hold, Bloomberg says
Subscribe for More Information
09:36 EDTPFEGlycoMimetics announces presentation of GMI-1271, rivipansel
Subscribe for More Information
09:28 EDTAGNActavis in active talks to acquire Allergan, Bloomberg reports
Actavis (ACT) is in active talks to acquire Allergan (AGN), Bloomberg reports, citing sources. Allergan earlier today disclosed in a filing that it has been approached by another party and that talks "may lead to negotiations." Shares of Allergan are up 1.1% to $198.50 in pre-open trading while Actavis is up 1% to $250.07. Valeant (VRX) is down 1.8% to $129.58. Reference Link
09:24 EDTAGNActavis in active talks to acquire Allergan, Bloomberg reports
Subscribe for More Information
09:12 EDTMRKMerck to present KEYTRUDA data
Subscribe for More Information
09:11 EDTAGNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Tesla (TSLA), up 0.6%... CBS (CBS), up 2.3%... Whole Foods (WFM) up 8.4%... American Capital (ACAS), up 9.5%... Horizon Pharma (HZNP) up 6.8%... Kate Spade (KATE), up 10%. ALSO HIGHER: Planar Systems (PLNR), up 70%, upgraded at Needham following the company's Q4 results... Tableau (DATA), up 9.8%, upgraded at RBC Capital following the company's Q3 earnings report... Allergan (AGN), up 1% after disclosing in new regulatory filing that discussions between the company and another unnamed party regarding a potential merger transaction have continued and "may lead to negotiations.” DOWN AFTER EARNINGS: Qualcomm (QCOM), down 6.9%... Zillow (Z), down 6.7%... PhotoMedex (PHMD), down 17.3%... Kulicke & Soffa (KLIC), down 7%... BioScrip (BIOS), down 5.8%. ALSO LOWER: Solazyme (SZYM), down 47%, downgraded at RW Baird, Pacific Crest and Cowen following the company's Q3 report... Genworth (GNW), down 23%, downgraded at Compass Point following the company's Q3 results... Cornerstone OnDemand (CSOD), down 19%, downgraded at various firms including William Blair and FBR Capital following the company's Q3 report.
09:09 EDTINFIInfinity announces presentation of new duvelisib preclinical data
Subscribe for More Information
09:06 EDTAGNAllergan says approach may lead to merger negotiations
Allergan (AGN) disclosed in new regulatory filing, “Notwithstanding the foregoing, we have been approached by another party regarding a potential merger transaction. Discussions between us and that party have continued and may lead to negotiations.” It has been reported that the unnamed party is Actavis (ACT). Allergan is attempting to fend off a hostile takeover by Valeant (VRX).
07:27 EDTMRKBIND announces agreement with Merck to develop Accurin nanomedicines
Subscribe for More Information
06:35 EDTPFEAstraZeneca CEO says tax revisions cripple new Pfizer offer, Reuters says
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use